Alyeska Investment Group
ACER

Alyeska Investment Group’s Acer Therapeutics Inc ACER Stock Holding History

Alyeska Investment Group’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-76,009
Closed -$1.64M – 533
2018
Q2 		$1.64M Sell
76,009
-13,389
-15% -$254K 0.01% 365
2018
Q1 		$1.72M Buy
89,398
+14,398
+19% +$264K 0.01% 360
2017
Q4 		$1.04M Buy
+75,000
New +$1.22M 0.01% 382

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alyeska Investment Group's ACER Position: Q3 2018 in Review

Alyeska Investment Group sold out of Acer Therapeutics Inc (ACER) in Q3 2018, closing a stake of 76,009 shares — an estimated $1.64M sold.

Alyeska Investment Group first reported a position in ACER in Q4 2017 and held it in 3 quarters. The position peaked at $1.72M in Q1 2018. 29 funds tracked by Wall St. Rank hold ACER as of Q3 2018.

  • Alyeska Investment Group reported no remaining Acer Therapeutics Inc position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 76,009 Acer Therapeutics Inc shares in Q3 2018, an estimated $1.64M.
  • Alyeska Investment Group first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 3 quarters.
  • Alyeska Investment Group's Acer Therapeutics Inc position peaked at $1.72M in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.